How to Empower Patients with T2D Knowledge and Introduce a GLP-1 RA
What do you need to know about a once-daily GLP-1 RA and what can you do to help your patients taking this T2D therapy? Join this multidisciplinary discussion with Jim Gavin, MD; Curtis Triplitt, PharmD; and Jeffrey Unger, MD, as they review the mechanism of action, dosing, efficacy, and safety of a once-daily GLP-1 RA for adult patients with T2D.
This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.
James R. Gavin III, MD, PhD is a clinical professor of medicine at Emory University, and chief medical officer of Healing Our Village, Inc. in Atlanta, Georgia.
Jeff Unger, MD, FAAFP, FACE, is a diplomate at the American Board of Family Practice, an assistant clinical professor of family medicine at UC Riverside School of Medicine, and director of Unger Concierge Primary Care Medical Group in Rancho Cucamonga, California.
Chris L. Triplitt, PharmD, CDCES, FADCES, is a clinical associate professor of medicine in the Division of Diabetes at University of Texas Health and Texas Diabetes Institute in San Antonio, Texas.